Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 20, 2025

Keywords

ClinConnect Summary

The TENDERS study is a clinical trial looking at how the timing of starting renal replacement therapy (RRT) affects patients with tumor lysis syndrome (TLS) who are experiencing acute kidney injury (AKI). TLS can happen after chemotherapy and can lead to serious imbalances in the body's chemicals, which may harm the kidneys. In this study, researchers will compare outcomes in patients who start RRT early versus those who start it later to see which approach leads to better kidney function after 30 days.

To participate in this trial, patients need to be adults aged 18 and older who are currently hospitalized in the ICU and have been diagnosed with a type of cancer that requires chemotherapy. They must also show signs of TLS based on specific laboratory tests. Patients and their families should know that this study is not yet recruiting participants, and those who join will help improve our understanding of the best timing for RRT in this critical situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged ≥18 years.
• • Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
• • Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
• • Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.
• Exclusion Criteria:
• • Patient or family opposition to data collection for research purposes.
• • Incomplete medical records that preclude data extraction.